Categories
Report

NITO

N2OFF Inc.

Check Out the Investor Presentation HERE

_________________________________________________

Hello Everyone,

We have a company that we wanted to bring to your attention right away.

We looked a this one just last month and we saw extreme upside action the day after we delivered you our report on the company.

Pull up NITO Immediately.

Yahoo has the entire float at just 2.78 Mil right now.

This may explain why we saw NITO explode roughly 100% the last time we profiled the company back in May.

When we brought it to your attention last time is saw an average trade on the session of .64.  After gapping up and opening at .75 the very next session, NITO exploded quickly to 1.30 before pulling back for roughly a 100% Move overnight.

Let’s take a look at the company again and research it immediately.

Post-harvest treatment of fruits and vegetables plays a critical role in maintaining their quality, extending shelf life, and reducing losses during storage, transportation, and distribution.

By implementing these certain treatments and management practices, producers and distributors can minimize losses, maintain product quality, and deliver fresh and nutritious fruits and vegetables to consumers worldwide.

N2OFF Inc. (formerly known as Save Foods, Inc.) is an innovative agri-food tech company that through its two operational arms delivers integrated solutions for improved safety, quality, and sustainability every step of the way from field to fork.

Save Foods Ltd., N2OFF’s 98% majority-owned subsidiary, Save Foods Ltd. focuses on post- and near-harvest treatments for fruits and vegetables to prevent contamination and extend shelf lifemajority-owned Israeli subsidiary, focuses on post-harvest treatments in fruit and vegetables to control and prevent pathogen contamination, significantly reduce the use of hazardous chemicals, and prolong fresh produce’s shelf life. NTWO OFF Ltd., N2OFF’s majority-owned Israeli subsidiary, contributes to tackling greenhouse gas emissions, offering a pioneering solution to mitigate emissions of nitrous oxide (N2O), a potent greenhouse gas with 265 times the global warming impact of carbon dioxide. NTWO OFF Ltd. aims to promote agricultural practices that are both environmentally friendly and economically viable. NITO is at the forefront of pioneering an innovative solution for farmers and fertilizer companies striving to reduce their environmental footprint.

With nine issued patents and six pending applications, Save Foods Ltd. recently gained approval from the California Department of Pesticide Regulation for its FieldProtect pre-harvest treatment. This approval opens doors for commercial expansion in California, where their previous trials on strawberries showed an 85% reduction in waste compared to industry standards.

NITO has also established a presence in Brazil, collaborating with Citrus Tree to treat over 20 tons of Tahiti limes.

NITO has A 60% majority-owned subsidiary, N2OFF Ltd. specializes in reducing nitrous oxide (N2O) emissions in agriculture. N2O is a potent greenhouse gas, about 300 times more powerful than carbon dioxide, significantly contributing to ozone layer depletion.

Understanding the necessity of mitigating harmful environmental impacts, they’ve developed a natural technology specifically tailored to significantly decrease nitrous oxide emissions in wheat crops. Their environmentally friendly solution is easy to apply and holds the promise of a cleaner future for all.

Their innovative technology is specifically designed to tackle nitrous oxide emissions in agriculture.

Through a pilot study in wheat crops, they have achieved significant reductions. Scaling our findings to larger fields, we aim to demonstrate substantial emission reductions and empower farmers and fertilizer companies to join the solution. They created N2OFF so the ozone could heal, agriculture could thrive, and a green world could bloom.

They understand the importance of reducing our N2O emissions without sacrificing crop yields or quality. That’s why they’ve developed a natural technology that significantly reduces nitrous oxide emissions in wheat crops. By adopting their solution, farmers and seed fertilizer companies will be able to unlock a valuable new revenue stream while contributing to a greener future.

�N2OFF Ltd. introduces two natural, plant-safe, and non-GMO bacteria strains into the soil to reduce N2O emissions. Recent studies showed a 54% reduction in N2O emissions in wheat crops in a greenhouse setting, marking a significant breakthrough.

� The company is expanding its innovative bacterial technology to corn, a crucial crop as the U.S. produces about one-third of the world’s corn. Plans are underway to implement and evaluate these solutions on a large-scale wheat farm.

N2OFF INC. Enters the Growing Solar PV Market and signs an Agreement with a Company of Seasoned Experts in the Field

The global solar photovoltaic (PV) market was estimated at USD 150 billion in 2022 and is predicted to hit over USD 383.78 billion by 2032

Neve Yarak, Israel, July 22, 2024 (GLOBE NEWSWIRE) — N2OFF, Inc.\ (NASDAQ: NITO) (FSE:80W) (“N2OFF”, or the “Company”), a clean- tech company offering sustainable solutions for various industries, announced today the expansion to the solar PV (photovoltaic) market, potentially proving investors lucrative assets alongside its innovation for the agri- tech market.

N2OFF partnered with Solterra Renewable Energy Ltd. (“Solterra”), a company founded in 2022 by Eran Litvak and Yair Harel, in the field of solar PV systems. Each of the founders is an expert in the field of solar PV, with a track record of dozens of successful projects. In addition, both are experienced entrepreneurs and managers with over 20 years of proven experience in identifying business opportunities, enhancing projects, and maximizing value in both the energy and financial sectors.

Solterra is currently active in three primary target markets: Italy, Poland, and Germany, managing a portfolio of at various stages of Solar PV development with a total cumulative capacity of approximately 300 megawatts.

“In recent months, we focused on the development of our subsidiary, NTWO OFF Ltd., which aims to reduce N₂O emissions using innovative bacterial technology for agriculture. In parallel, we identified what we believe is an attractive opportunity in the growing solar PV market. Our decision to enter this field was primarily driven by our collaboration with the experts from Solterra, who have experience in leading solar PV projects. The current loan agreement marks the beginning of a collaboration we believe could have great potential for profitability and revenue generation in future projects” David Palach, Chief Executive Officer of N2OFF.

According to Precedence Research, the global solar PV market was estimated at $150 billion in 2022 and is predicted to hit over $383.78 billion by 2032 and poised to grow at a CAGR of 9.90% during the forecast period from 2023 to 2032.

N2OFF entered into a loan agreement with Solterra and certain other private investors pursuant to which they committed to loan Solterra an aggregate of €500,000, of which €375,000 was committed by the Company.

NTWO OFF Achieved Positive Results of Over 22% improvement in Reduction of N2O Emissions in Open Greenhouse Environment

Recent greenhouse study resulted in a reduction of emissions of up to 54% compared to a previous study reduction of up to 44%

Neve Yarak, Israel, May 09, 2024 (GLOBE NEWSWIRE) — N2OFF, Inc.\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” or the “Company”), a pioneering agri-food tech company offering sustainable solutions for agriculture and plant-based food, announced that its subsidiary NTWO OFF Ltd., has achieved a groundbreaking milestone in its mission to mitigate agriculture’s environmental impact. A recent study conducted by NTWO OFF Ltd.’s research team has demonstrated remarkable success in its goal of reducing nitrous oxide (N2O) emissions from wheat crops.

The study transitioned from growth chambers to open greenhouse environments, allowing for larger pots and soil volumes. This adaptation facilitated the cultivation of more plants per pot and extended growth periods. The results exceeded expectations, with N2O emissions reduced by up to 54% compared to NTWO OFF Ltd.’s previous study result of emissions reduced by up to 44%, representing more than 22% improvement.

“We are thrilled by the outstanding performance of our innovative bacteria under open greenhouse conditions. The successful transition from the lab to an open greenhouse environment is a leap forward in our efforts to develop solutions for the reduction of N20 emissions in agriculture” said Dr. Dror Minz, of the ARO Volcani Institute and head of the research team.

NTWO OFF Ltd.’s proprietary technology revolves around two naturally occurring bacteria species isolated from wheat roots. These bacteria have demonstrated the ability to reduce N2O emissions across various environmental conditions. NTWO OFF Ltd. rigorously tests different formulations and soil types to optimize the effectiveness of this technology.

“Our commitment to environmental stewardship drives every aspect of our development. As the global community grapples with the challenges of climate change, NTWO OFF Ltd. remains steadfast in our dedication to providing innovative solutions for sustainable agriculture,” said David Palach, chief executive officer of N2OFF Inc.

According to Our World in Data, Nitrous oxide, often dubbed the “forgotten greenhouse gas”, poses a significant threat to the environment, being 265 times more potent than carbon dioxide in warming the planet. By pioneering solutions to mitigate N2O emissions, NTWO OFF Ltd. aims to play a pivotal role in combating climate change and promoting environmental sustainability.

Following the promising results achieved in its greenhouse experiments, NTWO OFF Ltd. is poised to expand its research efforts. Plans are underway to conduct larger-scale experiments in significantly larger containers, filled with various soil types. These endeavors aim to further validate the efficacy of NTWO OFF Ltd.’s technology across diverse agricultural settings.

N2OFF: Save Foods Received first order from a Peruvian Customer for its Eco-Friendly Solution for Fruits and Vegetables

Neve Yarak, Israel, May 01, 2024 (GLOBE NEWSWIRE) — N2OFF, Inc.\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” or the “Company”), a pioneer agri-food tech company offering sustainable solutions for agriculture and plant-based food, announced today that its subsidiary Save Foods Ltd. received its first purchase order from a customer in Peru, a leading grower, packer and distributor of avocado.

Save Foods’ eco- friendly solutions can be applied as a near and post-harvest solution for fresh produce to control pathogen contamination and prolong the shelf life of fresh produce while reducing the use of hazardous chemicals.

David Palach, Chief Executive Officer of N2OFF Inc. commented “During the last few years our customer conducted several post-harvest pilots where hundreds of tons of avocado were protected with Save Foods’ solutions. The purchase order from the Peruvian customer was received after the success of Save Food’s first commercial implementation of its solution during January 2024.

Mr. Palach added: The Latin American market represents a tremendous opportunity for Save Foods. With many countries in the region at the forefront of the global fresh produce market, we believe our products hold immense potential, whether utilized post-or near harvest. Our first order from Peru is particularly exhilarating, given the remarkable growth of Peruvian agricultural exports on the global stage, from a modest $645 million in 2000 to an impressive estimated $10.5 billion in 2023.”

N2OFF: Save Foods’ Innovative Technology Secures Patent Approval in South Africa, Strengthening Global Food Safety Efforts

In 2022, South Africa exported $1.85 billion in citrus, making it the second largest exporter of citrus in the world

Neve Yarak, Israel, May 28, 2024 (GLOBE NEWSWIRE) — N2OFF, Inc. (NASDAQ: NITO) (FSE:80W) (“N2OFF” or the “Company”), a pioneer agri-food tech company offering sustainable solutions for agriculture and plant-based food, as previously announced on March 28, 2024, one of Save Foods Ltd.’s patents has been granted in South Africa. This achievement emphasizes the Company’s ongoing commitment to global food safety and sustainability while expanding its geographical distribution.

The newly granted patent, “Sterilization Compositions and Methods for Use Thereof”, refers to kits and methods for controlling pathogen load within or on the surface of edible plant matter.

According to The Observatory of Economic Complexity, in 2022 South Africa exported $1.85 billion in citrus, making it the second largest exporter of citrus in the world. Concurrently, in 2022, citrus represented the 14th

NEWS

‍

MANAGEMENT TEAM

Adv. Shmulik Yannay

CEO

Meet Shmuel, a dynamic economist with a passion for cutting-edge technologies, entrepreneurship, and investment banking.

With experience as Director and Chief of Investment Banking at the American Yorkville Foundation, he brings a wealth of expertise to the table.

Shmuel holds a BA degree in Economics and an LL.B. degree in Laws from Hebrew University in Jerusalem, fueling his drive for innovation and success.

Shmuel holds an Israeli Bar license as Israeli lawyer.

Shlomo Zakai

CFO

Presently, Shlomo Zakai holds the position of Chief Financial Officer & Treasurer at Global Energy, Inc., Chief Financial Officer of UAS Drone Corp., Chief Financial Officer at Cuentas, Inc., Internal Auditor of F.M.S.

Enterprises Migun Ltd., Internal Auditor of Payton Industries Ltd.
and Chief Financial Officer of Save Foods Ltd.

Shlomo Zakai previously occupied the position of Financial Controller at N2OFF, Inc., Chief Financial Officer for Sonovia Ltd., Co-Chief Financial Officer-Israel & Treasurer at Blue Sphere Corp., Chief Financial Officer for Todos Medical Ltd., Senior Manager at Ernst & Young Global Ltd. and Accountant for Kost Forer Gabbay & Kasierer (a subsidiary of Ernst & Young Global Ltd.), Internal Auditor for Alarum Technologies Ltd.
and Internal Auditor of Ralco Agencies Ltd.

Mr. Zakai received an undergraduate degree from The College of Management Academic Studies

Dr. Dror Minz

Head of Research Team

With a strong academic background, Dror is a distinguished researcher and educator in the field of environmental sciences. He completed his studies at Tel Aviv University before pursuing postdoctoral research at Northwestern University in Evanston, IL, and the Max Planck Institute in Bremen, Germany.

Currently serving as a researcher at the Institute for Soil, Water, and Environmental Sciences, he also imparts his knowledge as a teacher at the Hebrew University.

Dror has made significant contributions to the field, having supervised 23 MSc and PhD students, mentored 11 postdoctoral fellows, and authored over 100 scientific papers.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND FIVE HUNDRED USD BY LFG EQUITIES CORP FOR A ONE DAY NITO AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

SYNX

SYNX Has Received Roughly $4 Million in Orders from the IDF & Israeli Police Since the Start of the War

The company has estimated revenues for the six months ended June 30, 2024 to be approximately $5.31 million, highlighting tremendous growth

Silynxcom Secures Multiple Orders from US Federal and Law Enforcement Organizations of its New Tactical System

Revenues for the year ended December 31, 2023 increased to $7.6 million, up 5% from the previous year, reflecting the Company’s ongoing expansion and product adoption

Preliminary unaudited revenue for the three months ended March 31, 2024, that is estimated at $3.525 million, representing an estimated increase of more than 100% compared to the same period in 2023

READ THE INVESTOR PRESENTATION HERE

__________________________

‍

Hello Everyone,

We have another company for youth research for Thursday’s session.

It has been a little bit since we last took a look at a defense company. We love this sector and are always excited to put an undiscovered company on your plate so that you can research it.

Pull up SYNX Immediately.

The company put out some substantial news today that you can read down below. The news had major impact, sending SYNX exploding double digits and almost breaching the 4 buck level.

SYNX has a great story behind it.

Since it’s inception, the company has achieved over $150M in revenue from iconic government defense institutions like the CIA, U.S. Army and Marine Corps.

It is estimated that roughly 17% of returning veterans suffer from some form of hearing loss.

Just in March, 250,000 vets reached a $6 billion settlement of a class-action lawsuit alleging popular earplugs used in the Iraq and Afghanistan wars were faulty.

The products are compatible with most radios, smartphones, and intercom systems, including encrypted channels used by tactical and law enforcement units.

Silynx headsets are used by elite US and international warfighters, all levels of law enforcement, including federal, state, and local, and international public safety and security forces. Silynx headset systems protect against impulse and steady-state noises while enabling the user to hear ambient noises, via “hear-thru” functionality, and maintain 360° situational awareness.

Working closely with end users, Silynx integrates feedback from the field into all of its solutions. Compatible with standard military and law enforcement radios and available with a broad range of unique accessories, Silynx headsets can be used in any mission setting, mounted/dismounted, maritime, airborne, or low-vis operations. Silynx solutions provide users with an unparalleled operational edge. Silynx is committed to constant innovation and improvement of products and ideas to meet the continually changing requirements of operators.

Silynxcom Receives New Order Further Expanding Presence in Military Tactical Communication Equipment Market

The tactical sound protection headset market is projected to reach $3.8 Billion by 2027

Company received accumulated orders of approximately $815,000 from the Israel Defense Forces since the beginning of July 2024

Netanya, Israel, July 24, 2024 (GLOBE NEWSWIRE) — Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices has received an additional order from the Israel Defense Forces (“IDF”) for its advanced tactical communication headset devices. This latest order for $315,000 comes after a $500,000 order (both amounts approximate based on current exchange rates) from the IDF was announced by the Company on July 9, 2024. The Company also recently announced on July 9, 2024, a strong performance for the first half of 2024 on a preliminary unaudited basis, including estimated revenue for the six months ended June 30, 2024 of approximately $5.31 million – highlighting accelerated operational and business growth – and cash and cash equivalents and marketable securities of approximately $3.69 million as of June 30, 2024.

Nir Klein, Chief Executive Officer of Silynxcom, said “We are proud to report another order for our advanced tactical communication headset devices from the IDF. We are excited about the opportunity to continue scaling up our revenue growth into our addressable market that is estimated to reach $3.8 billion by 2027 according to the Global Tactical Headset Market Research Report, published by Wantstats Research and Media Pvt Ltd.”

Silynxcom’s tactical communication headset devices are designed to meet the rigorous demands of modern militaries, law enforcement units and industrial and commercial plants.Silynxcom’s products ensure more efficient and safer high-quality audio, clarity and robust communication.

The above preliminary financial information is based upon the Company’s estimates and is subject to completion of its financial closing procedures. Moreover, this preliminary financial information has been prepared solely on the basis of information that is currently available to, and that is the responsibility of, management. The Company’s independent registered public accounting firm has not audited nor reviewed, and does not express an opinion with respect to, this information. This preliminary financial information is not a comprehensive statement of the Company’s revenue and cash and cash equivalents for the six months ended June 30, 2024 and remains subject to, among other things, the completion of the Company’s financial closing procedures, final adjustments, and completion of its internal review for the six months ended June 30, 2024, which may materially impact the results and expectations set forth above. As a result, this preliminary unaudited financial information may differ from the actual results that will be reflected in the Company’s results of operations and financial position as of and for the six months ended June 30, 2024 when they are completed and publicly disclosed. This preliminary unaudited financial information may change. Accordingly, you should not place undue reliance upon these preliminary unaudited estimates.

Silynxcom Secures Multiple Orders from US Federal and Law Enforcement Organizations of its New Tactical System

Netanya, Israel, June 18, 2024 (GLOBE NEWSWIRE) —   Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices as well as other communication accessories, announced that its latest tactical communication system is gaining traction in the U.S. market. Multiple law enforcement and federal organizations have placed orders for the new system, which the Company believes highlights the product’s effectiveness and reliability.

The new In-Ear Headset system, designed to meet the unique requirements of law enforcement and public safety organizations, represents a major innovation in secure and encrypted communication. Compatible with “Project 25 (P25)” and “TETRA”- Terrestrial Trunked Radio communication systems, widely used across the globe, the system ensures seamless integration and superior performance.

Highlights:

Innovative Product Launch: Silynxcom’s latest offering taps into the massive law enforcement communication market, showcasing the Company’s commitment to innovation and its ability to develop products that meet critical market needs.

First-Mover Advantage: With this new system, Silynxcom secures a first-mover advantage in providing high-quality, encrypted communication solutions for law enforcement agencies, offering significant growth potential within the sector.

Market Expansion: These orders pave the way for Silynxcom to expand its footprint globally, particularly in the lucrative European law enforcement market. The Company is strategically positioned to capitalize on new opportunities, aiming to broaden its reach and penetrate new segments within the government sector.

Product Differentiation: The In-Ear Headset system sets a new industry standard with features like superior audio quality, compatibility with a wide range of radio devices, and seamless integration into law enforcement workflows. This differentiation strengthens Silynxcom’s competitive edge and market positioning.

Silynxcom Announces Annual Results for 2023; Positive Cash Flow and Revenue Growth

NETANYA, Israel, April 30, 2024 (GLOBE NEWSWIRE) — Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices as well as other communication accessories, has released its consolidated financial results for the full year period ended December 31, 2023. The Company has filed its Annual Report on Form 20-F for the year ended December 31, 2023 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”), which can be accessed on its website at https://www.silynxcom.com/. Shareholders may request, free of charge, a hard copy of the Annual Report, which includes Silynxcom’s complete audited consolidated financial statements for the year ended December 31, 2023, by contacting ir@silynxcom.com.

Key Financial Highlights for 2023:

  • Cash and Cash Equivalents- On January 12, 2024, Silynxcom successfully completed its initial public offering (“IPO”), raising $5 million by issuing 1.25 million ordinary shares, adding to a year-end cash balance of $568 thousand, up from $69 thousand in the previous year, demonstrating strong liquidity to support ongoing investments and operations.
  • Positive Cash Flow from operating activities amounted to $730 thousand, compared to cash flow used in operating activities of $1.7 million in 2022.
  • Operating loss Operating loss for 2023 was $2.8 million, compared to an operating profit of $480 thousand in 2022, reflecting heightened investments in R&D and market expansion efforts. Non-IFRS operating profit amounted to $1.4 million, representing an increase of more than 200% compared to $480 thousand in 2022. A reconciliation between operating profit (loss) and non-IFRS operating profit (loss) is provided in Appendix A to this press release.
  • Net loss Net loss for the year ended December 31, 2023 was $2.8 million, compared to a net income of $1.8 million in 2022 that included $1.2 million in finance income from warrant buybacks. Non-IFRS net income for the year ended 2023 totaled $1.3 million, representing growth of more than 150% year over year compared to $561 thousand in 2022. A reconciliation between net income (loss) and non-IFRS net income is provided in Appendix A to this press release.
  • Revenues for the year ended December 31, 2023 increased to $7.6 million, up 5% from the previous year. This growth reflects the Company’s ongoing expansion and product adoption.

“2023 was a year of business expansion, growth and strategic investment for Silynxcom, followed by becoming a listed company on the NYSE following a successful IPO in January 2024,” said Nir Klein, Chief Executive Officer of Silynxcom. “Our revenue increased alongside becoming cashflow positive, which we believe underscores our successful market expansion and enhanced financial stability.”

“In 2023, we laid the foundation for new and advanced products and increased compatibility for leading systems in our target markets. In addition, we forged new partnerships with key players in the global defense and law enforcement sectors, which already led to purchase orders in 2024,” added Mr. Klein.

Recent Corporate Highlights:

  • In April 2024, the Company announced the strengthening of its collaboration with 3M PELTOR to deliver next generation headset solutions.
  • The Company entered new markets in East Asia and Asia Pacific.
  • Since October 2023, the Company has secured orders exceeding $4.85 millionfrom one Israel Defense Forces and Israeli police forces.
  • In February 2024, the Company disclosed a third order from a leading global defense firm, bringing its total orders from this client to over $4.5 million.
  • The Company received its first order for the newly designed in-ear headset with an encrypted security system intended for use by law enforcement.
  • In March 2014, the Company launched a new system for law enforcement, compatible with commonly used terrestrial trunked radio (“TETRA”) and P25 systems.

Use of Non-IFRS Financial Results

In addition to disclosing financial results calculated in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board, this press release contains certain financial measures that are not prepared under IFRS. These measures may be different from non-IFRS financial measures used by other companies. The Company defines non-IFRS operating profit (loss) as operating profit (loss) excluding the effect of share-based compensation expenses. The Company defines non-IFRS net income as net income (loss) excluding the effect of share-based compensation expenses and the revaluation of a liability in respect of warrants. The Company’s management believes the non-IFRS financial information provided in this press release is useful to investors’ understanding and assessment of the Company’s ongoing operations. Management also uses both IFRS and non-IFRS information in evaluating and operating business internally and as such deemed it important to provide all this information to investors. The non-IFRS financial measures disclosed by the Company should not be considered in isolation or as a substitute for, or superior to, financial measures calculated in accordance with IFRS and the financial results calculated in accordance with IFRS and reconciliations to those financial statements should be carefully evaluated. Reconciliations between IFRS measures and non-IFRS measures are provided in Appendix A to this press release.

Silynxcom Estimates Revenue Growth of More Than 100% for the First Quarter of 2024

Netanya, Israel, May 13, 2024 (GLOBE NEWSWIRE) —  Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices as well as other communication accessories, today provided preliminary unaudited financial results as of and for the three months ended March 31, 2024.

On a preliminary unaudited basis, Silynxcom is reporting a strong performance for the first quarter of 2024, highlighting accelerated operational and business growth including:

  • preliminary unaudited revenue for the three months ended March 31, 2024, that is estimated at $3.525 million, representing an estimated increase of more than 100% compared to the same period in 2023; and
  • preliminary unaudited cash and cash equivalents as of March 31, 2024, that amounted to $4.353 million.

“We are proud to report remarkable preliminary results, marked by significant revenue growth. This success has been fueled by our expansion in our marketing efforts, our customer base and our new innovative products. Recent geopolitical events strengthen demand for effective and safe solutions for tactical communication, increasing global awareness of our advanced capabilities,” said Nir Klein, Silynxcom’s Chief Executive Officer.

The above figures represent preliminary unaudited estimates and final quarterly reporting results may vary. The preliminary unaudited results presented reflect the Company’s estimates based solely upon information available and the Company’s final results may differ from these preliminary estimates due to the completion of the Company’s financial closing procedures, final adjustments and other developments that may arise between now and the time such final unaudited financial information is issued. The foregoing forward-looking statements reflect the Company’s expectations as of today’s date.

‍

NEWS

  • Silynxcom Receives New Order Further Expanding Presence in Military Tactical Communication Equipment Market
  • 2 hours ago
  • Silynxcom Receives $500,000 in Orders from the Israel Defense Forces
  • Jul 9, 2024
  • Silynxcom Secures Multiple Orders from US Federal and Law Enforcement Organizations of its New Tactical System
  • Jun 18, 2024
  • Silynxcom Expands Global Reach with New Asian and European Distribution Agreements
  • Jun 12, 2024
  • Silynxcom’s New Product Gaining Momentum in Europe with New Order
  • May 29, 2024
  • Silynxcom Estimates Revenue Growth of More Than 100% for the First Quarter of 2024
  • May 13, 2024
  • Silynxcom and 3M PELTOR Further Collaborate for Latest Innovative Solution, the ComTac™ VIII Headset
  • May 7, 2024
  • Silynxcom Announces Annual Results for 2023; Positive Cash Flow and Revenue Growth
  • Apr 30, 2024
  • Silynxcom Won First Order for its Revolutionary In-Ear Headset System, Marking a Leap in Law Enforcement Communication Technology
  • Apr 11, 2024
  • Silynxcom Wins Order for German Police Department Ahead of High-Profile International Sports Event
  • Apr 9, 2024
  • Silynxcom Wins Order for German Police Department Ahead of High-Profile International Sports Event
  • Apr 9, 2024
  • Silynxcom and 3M PELTOR Strengthen Collaboration to Deliver Next Generation Headset Solutions
  • Apr 1, 2024
  • Silynxcom Delivered an Order for Special Forces Military Unit in Asia Pacific, Expanding Global Footprint
  • Mar 28, 2024
  • Silynxcom Secures First Order of its New In-Ear Headset System Designed for Law Enforcement
  • Mar 14, 2024
  • Silynxcom Unveils Groundbreaking Headset for Military Dogs, Offering Unparalleled Protection and Communication
  • Feb 29, 2024
  • Silynxcom Delivers $280,000 Repeat Order from Military Customer
  • Feb 27, 2024
  • Silynxcom Introduces New Encrypted Wireless Tactical Communication Product
  • Feb 22, 2024
  • Silynxcom Receives First Order for Advanced SDR Headset from Leading US-Based Military Radio Manufacturer
  • Feb 20, 2024
  • Spotlight: Silynxcom CEO Explains Why 2024 Could Be A Breakout Year
  • Feb 15, 2024
  • ‍

    SINCERELY,

    DISCLAIMER

    THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

    OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SHORE THING MEDIA LLC FOR A ONE DAY SYNX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

    Categories
    Report

    NNVC

    Targeted Virus-Killing Nanomedicines (PRNewsFoto/NanoViricides, Inc.)

    READ THE INVESTOR PRESENTATION HERE

    ___________________________

    Hello Everyone,

    We have a new profile that we want you to put back on your radar for Wednesday’s session.

    You are definitely going to remember this one.

    This is a company we showed you back in May when it was well under 2 bucks. Then we looked at it again in early June when it was under 2.50 and went on to hit 3.60 just a few sessions later for at quick 40%+ move.

    It is on the run again, closing green 5 of the last 6 sessions.

    NanoViricides, Inc. (NYSE American: NNVC) looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology.

    Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031.

    NANOVIRICIDES are better because they destroy viruses and their variants without relying on the patient’s immune system, thereby making them effective for populations that include geriatric and pediatric patients.

    Antibodies only bind by two points to the virus, and destruction of the complex requires effective immune function, which is not the case in sick patients..

    Vaccines only train the body into producing antibodies against the virus in the vaccine. Antibodies and vaccines are easily overcome by viruses by mutating in the field, hence the need for annual influenza vaccine updates.

    NNVC is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-CoV-2 for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Our other advanced candidate is NV-HHV-1 for the treatment of Shingles (previously referred to as NV-HHV-101). The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-CoV-2 into Phase I/II human clinical trials. NV-CoV-2 is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-CoV-2 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses and/or enteroviruses if the initial research is successful. The Company’s technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

    RECENT COMPANY HIGHLIGHTS:

      • NanoViricides, Inc’s lead drug, NV-387, is in Phase 1 clinical trials.
      • Broad spectrum antiviral NV-387 showing promise against many virus families including and beyond Tripledemic (i.e. COVID-19, RSV, FLU) .
      • No adverse events in Phase I SAD and MAD studies even at the highest dose 40mg/Kg
      • Found to be non-immunogenic, non-mutagenic, non-allergenic, and non-phototoxic.
      • Strong safety allows use in pediatrics, adults with co-morbidities, and immune-compromised patients unlike limitations of products currently in the market.  
      • Developed Oral Syrup and Oral Gummies (soft solids) – good for geriatric and pediatric patients
      • Drugs expected to continue to be effective even as the virus generates variants – unique receptor site doesn’t change
      • Technology mimics unique receptor site used by virus; delivers to specific targets using receptor-recognition (no bulky antibodies)

    A New Era in Targeted Anti-Viral Therapeutics

    NanoViricides rang the opening bell of the New York Stock Exchange on Aug. 13, 2014. In the front center (left to right) are Meeta Vyas, Anil Diwan and Dr. Eugene Seymour.

    NanoViricides, Inc. is a globally leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody. In addition, the nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is the only technology in the world, to the best of our knowledge, that is capable of both (a) attacking extracellular virus, thereby breaking the reinfection cycle, and simultaneously (b) disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.

    Our anti-viral therapeutics, that we call “nanoviricides®” are designed to appear to the virus like the native host cell surface to which it binds. Since these binding sites for a given virus do not change despite mutations and other changes in the virus, we believe that our drugs will be broad-spectrum, i.e. effective against most if not all strains, types, or subtypes, of a given virus, provided the virus-binding portion of the nanoviricide is engineered appropriately. Viruses would not be able to escape the nanoviricide by viral mutations since they continue to bind to the same cellular receptor and thus would be captured by the nanoviricide. Virus escape by mutations is a major problem in the treatment of viral diseases using conventional drugs.

    Versatile Platform Technology

    A nanoviricide is created by chemically attaching a virus-binding ligand, derived from the binding site of the virus on its cell surface receptor, to a nanomicelle flexible polymer. This binding site does not change significantly when a virus mutates

    Tailor-made design and selection of (1) the virus-binding ligand; and (2) the backbone “nanomicelle”, separately, allows us to rapidly optimize drug candidates (a) against a number of viruses; (b) for desired pharmacokinetic characteristics (e.g. sustained effect); and (c) for different routes of administration. This versatility is unmatched in the Industry.

    Virus-specific nanoviricides have been created against important viruses such as HIV, Influenza and Bird Flu by choosing highly virus-specific ligands

    Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known viruses. The Company is developing broad-spectrum nanoviricides to combat several neglected tropical diseases, such as Dengue, Rabies, and Ebola/Marburg. This is similar to antibiotics such as penicillin against bacteria that exploit a feature common to all bacteria.

    A NanoViricide® Attacking a Virus Particle: Unique, Novel, Nanotech Design

    bindingimage

    A single nanoviricide micelle may be capable of completely engulfing a Virus Particle. Nanoviricide micelles self-assemble from multiple chains. A single chain micelle shown for convenience. Illustration not to scale.

    Each nanoviricide drug is designed as an antiviral agent specifically targeted for a particular type of virus or group of viruses. Most existing anti-viral agents are known to have non-specific effects against both host cells and viral machinery at the same time often leading to side effects. Most current anti-viral agents act inside human cells. It is believed that this intracellular mechanism leads to significant opportunities for unwanted side effects against host cells. Nanoviricides, on the other hand, are designed to work directly against virus particles in bodily fluids. The Company believes that this approach may make nanoviricides inherently safer than existing approaches.

    A nanoviricide is designed to seek and attach to a specific virus particle, engulfing the virus particle in the process, thereby rendering it incapable of infecting new cells, and disabling it completely. This suggested mechanism of action encompasses much more than what the current entry and fusion inhibitors are expected to do. The fusion and entry inhibitors do not completely cover the virus particle, likely blocking only a few sites on the virus particle. This means the virus particle may still be capable of infecting cells using its unblocked attachment sites. In contrast, a nanoviricide, because of its larger size and flexible nature, is expected to engulf the virus particle completely, thus disabling the virus particle. The action of a nanoviricide, if it works as designed, may be expected to be superior to antibody agents that attack viruses. Antibodies, being large, are expected to block relatively greater portions of the virus particle surface compared to small molecule entry inhibitors. However, antibodies depend upon the human immune system responses for clearing the virus particle. In contrast, nanoviricides are thought to be capable of acting as completely programmed chemical robots that finish their task of destroying the virus particle on their own.

    NV 387 IN CLINICAL TRIALS

    The drug, developed in response to the COVID-19 pandemic, demonstrated exceptional safety in clinical trials, even at the highest dose levels, with NO adverse events reported. The unique mechanism of action involves mimicking a cell membrane, encapsulating and blocking the virus.

    Beyond COVID-19, the drug also displayed promising results against respiratory syncytial virus (RSV), offering a potential solution for infants and seniors where existing treatments like ribavirin may be contraindicated due to side effects.

    The clinical trials involved both oral tablets and oral gummies, catering to various age groups, including pediatrics. NV 387 exhibited broad-spectrum activity against multiple strains of coronaviruses, showcasing effectiveness 10 times greater than remdesivir in preclinical studies.

    The ongoing clinical trial progress and positive results position NanoViricides at the forefront of antiviral drug development, marking a significant milestone in their journey from preclinical research since 2005 to clinical trials.

    The company believes that NV-387 not only binds to the virus, but fuses with the virus surface, uprooting the glycoproteins that are required for the virus to bind to the human cell (for example, the S protein, and its products S1 and S2 proteins from coronaviruses), thereby rendering the virus incapable of infecting a cell. In contrast, antibodies are only capable of covering the virus, generally incompletely, and require immune system assistance for clearing the resulting complex!

    NV-387 ADDRESSES AN UNMET MEDICAL NEED FOR BROAD-SPECTRUM, SAFE AND EFFECTIVE ANTIVIRAL DRUG THAT WORKS AGAINST MULTIPLE VIRAL THREATS:

    There is a significant unmet medical need for a broad-spectrum antiviral drug that is effective and useable in all segments of the population. There are substantial limitations for all currently approved COVID drugs in terms of both the eligibility of a COVID patient, and the effectiveness of the drug.

    NNVC believes that the excellent safety and the distinctly different mechanism of NV-CoV-2 (NV-387) support the use of this drug across all patient populations. This is an important characteristic for a COVID drug as well as for a drug to treat RSV infection.

    NV-387 ADDRESSES LARGE MARKET SIZES:

    Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031*.

    *Source: Transparency Market Research

    The market size for RSV therapeutics was estimated to be $2 Billion in 2023 and is expected to rise to exceed $8.5 Billion by the year 2031**.

    **Source: Growth+ Market Reports.

    NANOVIRICIDES TECHNOLOGY WILL TRANSFORM THE WAY VIRUSES & THEIR VARIANTS ARE TREATED WORLDWIDE!

    NNVC’s novel approach has already enabled variant-proof drugs, blocking the complete viral life cycle without requiring help from the host’s defense systems! If both the viral re-infection cycle, and viral replication cycle arms of the viral lifecycle are blocked, a cure for many viral diseases is possible!!

    The Company’s virus-specific nanoviricides have been created against important viruses such as HIV, Influenza and Bird Flu by choosing highly virus-specific ligands.

    Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known viruses. The Company is also developing broad-spectrum nanoviricides to combat several neglected tropical diseases, such as Dengue, Rabies, and Ebola/Marburg.

    A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox – NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides

    SHELTON, CONNECTICUT – Wednesday, May 8, 2024 — NanoViricides, Inc. (NYSE Amer.: NNVC) (the “Company”), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes activity against orthopoxvirus family (Smallpox/Mpox), with both inhalation and skin abrasion (sexual) modes of infection acquisition. Ectromelia virus infection of mice is a model for Smallpox infection in humans, and also serves as a surrogate for MPox infection in humans. All three viruses belong to the orthopoxvirus family.

    NanoViricides reports that in a lethal animal model of lung infection by Ectromelia virus, oral dosing with NV-387 led to an increase in lifespan of mice that was comparable to oral treatment with tecovirimat (TPOXX®, SIGA), the approved drug against Smallpox.

    This lung infection study substantiates the results of the previously reported intradigital footpad infection study that: (i) NV-387 has comparable antiviral activity as tecovirimat, and
    (ii) NV-387 plus tecovirimat has much stronger antiviral activity than either drug alone.

    We have completed a lethality animal study wherein animals were infected with ectromelia virus into the lungs directly. In this study, we found that NV-387 alone treated animals survived 15 days, tecovirimat alone treated animals survived 16 days, and NV-387 plus tecovirimat treated animals survived 19 days, whereas vehicle-treated animals died in 8 days.

    This lung-infection study emulates infection from aerosolized dispersion of the virus, as may be expected in a bioterrorism scenario.

    Survival Lifespan of Lethally Infected Mice – Lung Infection with Ectromelia Virus

    Previously, on November 14, 2023, we have reported that in a lethal intradigital footpad infection of mice with ectromelia virus, oral NV-387 treatment led to lifespan improvement comparable to oral tecovirimat treatment, with both treatments resulting in 14 days survival, whereas vehicle treated animals died in 8 days. Moreover, combined treatment with both NV-387 and tecovirimat resulted in a significantly improved survival of 17 days in this study.

    Survival Lifespan of Lethally Infected Mice – Intradigital Footpad Infection with Ectromelia Virus

    This intradigital footpad infection study emulates the skin-to-skin transfer of the virus as in sexual transmission, such as that in the case of current Clade 1 MPox virus epidemic in the DR Congo; Clade 1 MPox is more deadly than the Clade 2 MPox; the latter had caused a small pandemic recently with sexual mode of transmission (https://www.sciencefocus.com/news/monkey-pox-new-strain , May 5, 2024).

    Tecovirimat is the drug approved for smallpox under “animal rule” and is stockpiled by the Biomedical Advanced Research and Development Authority (BARDA). It was mobilized from the stockpile during the recent MPox Clade 2 pandemic. BARDA is interested in development of additional poxvirus therapeutics as per a recent Broad-Agency Announcement (BAA). There is significant interest in the development of a smallpox therapeutic that works well by itself, as well as in combination with the known drug, tecovirimat. Tecovirimat has a low barrier of escape; a single mutation in one protein can enable the virus to escape this drug, adding to the significance of additional smallpox drug development.

    Therefore we believe that NV-387 is a viable clinical candidate to be developed by itself for the treatment of poxvirus infections under the US FDA “Animal Rule”. In addition, we believe that the combination of NV-387 and tecovirimat could reduce the potential for escape resistant generation against tecovirimat, as is known with other drug combination studies against viruses.

    A safe and effective antiviral drug that the virus would not escape by simple mutations or field evolution is the holy grail of antiviral drug development. We believe that the NanoViricides Platform technology meets this challenge.

    NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections

    SHELTON, CONNECTICUT – Monday, July 1, 2024 — NanoViricides, Inc. (NYSE Amer.: NNVC) (the “Company”), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its current assets and plans towards becoming a successful pharmaceutical company intending to revolutionize the treatment of viral infections.

    NV-387, our lead broad-spectrum antiviral drug candidate has completed Phase I clinical trial in healthy subjects with no drop-outs and no reported adverse events, indicative of excellent safety and tolerability in humans.

    This single drug, NV-387, has been found to be highly active against a number of different types of viruses. In fact, its activity has, in animal models:
    • Resulted in curing lethal lung RSV infection;
    • Substantially bested the activities of approved drugs (Tamiflu, Xofluza, Rapivab) for Influenza;
    • Substantially bested the activity of Remdesivir against lethal coronavirus infection; and
    • Matched the activity of TPOXX against poxvirus.

    We believe that this ultra-broad-spectrum antiviral activity of NV-387 became possible because NV-387 is designed to mimic an invariant host feature that over 90% human pathogenic viruses employ for attachment and infection.

    A single antiviral drug that can effectively treat almost any respiratory viral infection would be a revolutionary development in the treatment of viral diseases, reminiscent of the revolution caused by penicillin in the treatment of bacterial infections, we believe.

    We are rapidly moving towards Phase II studies to establish effectiveness against a viral disease in humans. We plan on Phase II studies for RSV, with the goal of developing a therapeutic for the treatment of pediatric patients, which is the greatest unmet need in RSV infection.

    The market sizes for the viral diseases that NV-387 has already been found to be a viable clinical drug candidate as above are substantial.

    The market size for RSV is estimated at $2.6 Billion in 2024, growing to $4.3 Billion in three years, at a rate of 18.9% as reported by GrowthPlusReports.

    The market size for Influenza and Bird Flu is estimated at $4.6 Billion in 2024, growing to an estimated $5.9 Billion in three years, at a rate of 8.5% as reported by DelveInSight. In case a pandemic occurs, reality may outrun such projections by magnitudes, as was seen with the COVID pandemic.

    1. https://www.growthplusreports.com/report/respiratory-syncytial-virus-rsv-therapeutics-market/8519

    2. https://www.delveinsight.com/report-store/influenza-a-infections-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

    The market size for COVID, as it has become an endemic disease by now, can be expected to be similar to the market size for Influenza while new COVID drugs are being developed, since COVID continues to cause at least twice as large a fatality rate as Influenza in the USA alone.

    Thus we estimate an overall market size of around $16 Billion in three years for these three viruses, that NV-387 is expected to tackle.

    Thus NV-387 alone is poised to propel NanoViricides towards great success in a near-term horizon. We plan to license or co-develop our various drug candidates against multiple viral diseases to other Pharma Companies. In addition, we plan on seeking non-dilutive funding for the development of drugs that are of interest for biodefense.

    We have already demonstrated the ability to manufacture our own drug candidates at several Kilograms scales in cGMP-compliant processes for clinical trials. Our campus comprises a multi-Kg scale cGMP-compliant manufacturing facility with Class 100 clean rooms. We have demonstrated capabilities for manufacture of the drug substance, and thereafter formulate, fill-finish-and-package the drug products for clinical trials in this facility.

    We believe that our existing manufacturing facility would be adequate for market entry of NV-387 for the pediatric patients segment when the drug is approved by the FDA.

    We also have a drug in development against herpesviruses, NV-HHV-1, formulated as a skin cream, that we plan on advancing through clinical trials for regulatory approval as a topical treatment of Shingles/Chickenpox skin rashes, HSV-1 “cold sores”, as well as HSV-2 “genital ulcers”. NV-HHV-1 had completed IND-enabling studies by October 2019 just before the COVID-19 pandemic broke out, whereupon we took up the challenge of developing a highly effective drug to treat all coronavirus infections. We have an oral formulation of NV-HHV-1 in development for systemic use to treat herpesvirus infections.

    Our unique, host-mimetic, directly virus-attacking, technology platform has enabled the development of a number of drug candidates against several viral diseases. We believe these developments will continue to provide additional drug candidates to feed our pipeline for several years to come.

    Thus, we believe that we are on the verge of substantial success and expansive growth in the near future:
    • having successfully completed Phase I of our first drug candidate,
    • having amassed substantial data demonstrating superior antiviral activity of our drug candidates in animal models,
    • and now being poised to enter into Phase II human clinical trials.

    Orally Administered NV-387 Results in Ideal Flat Blood ConcentrationProfile for Sustained Antiviral Effect -A First-In-Class, Broad-Spectrum Antiviral Agent Intending ToRevolutionize Treatment of Viral Infections Including RSV, COVID,Influenzas and More

    SHELTON, CONNECTICUT – Tuesday, June 11, 2024 — NanoViricides, Inc. (NYSEAmer.: NNVC) (the “Company”), a clinical-stage global leader in broad-spectrum antiviralnanomedicines, reports that its clinical stage lead nanoviricide broad-spectrum antiviral drugcandidate, NV-387, results in an ideal flat blood concentration profile for an extended time periodupon oral administration in two different animal models.This unusual but highly desirable, extended flat time profile of blood concentration of orallygiven NV-387 enables sustained antiviral effect over a long period of time, allowing infrequentdosing regimens.
    The blood concentration of NV-387 increased to a peak in approximately the first hour, and thenremained almost constant for eight hours or longer, thereafter, the concentration declined to reachbaseline at about twelve hours; upon oral administration of a first dose of NV-387. This wasfound to be the case in studies involving two different animal models, namely, rats and dogs.After repeated dosings, the plateau of the sixth dose lasted for at least 24 hours, thereafterdeclining to baseline at about 36 hours, in both the rat and dog animal models.The same plateau profile phenomenon was observed in both male and female animals, as well asin both species of animals, namely, rat and dog.
    The blood concentration profile of NV-387 is indicative of the formation of a buffering reservoirof the drug in the host that releases the drug at a regular rate into the bloodstream.The Company has recently reported that NV-387, when given as a slow bolus intravenousinfusion, was found to result in a relatively flat plateau of blood concentration of the drug withvery slow decline over a 24 hour period in a cynomolgus monkey model.The flat time profile of NV-387 indicates that even at very high dosings, its blood concentration isunlikely to result in unwanted side effects. Typical drugs result in a rapid rise in bloodconcentration of the drug in generally the first hour to a peak, thereafter rapidly exponentiallydecreasing to baseline in 3-6 hours. In order to ensure that the concentration of the drug issufficiently high to provide antiviral effect at say 2-4 hours from dosing, the drug dose chosenwould be relatively high, and can therefore result in a substantially greater drug concentration inthe beginning, which can result in unwanted side effects. Therefore, a sustained, nearly flat drugconcentration profile is highly sought-after.
    In the repeat-dose oral NV-387 administration studies in both rat and dog models cited above, twodoses were given on the first day (at 0h and 12h), followed by third dose at 24 h, and then dailydoses at 24 hour intervals, for a total of six doses in five days.
    The Company has previously reported that NV-387 when administered orally resulted in strongantiviral effects in several respiratory viruses. In lethal infections with hCoV- NL63 (a model forSARS-CoV-2, cause of COVID), RSV, as well as Influenza A/H3N2, orally administered NV-387was found to be superior to approved therapeutics where available.
    In fact, the Company has found that NV-387 enabled complete cure of RSV infection in themouse model of lethal lung infection with RSV A2.
    The Company therefore believes that NV-387 is a first-in-class, broad-spectrum antiviral agentthat could be a revolutionary single drug for the treatment of a multitude of respiratory viralinfections including RSV, COVID, Influenzas and potentially other viruses.
    The presented non-clinical studies of pharmacokinetics of orally administered NV-387 providesupport that the strong antiviral effect seen in these antiviral animal model efficacy studies is theresult of NV-387 circulating in the body and exerting its direct antiviral effects.”NV-387 is a unique host-mimetic, direct acting antiviral drug that the virus is highly unlikely toescape,” said Anil R. Diwan, Ph.D, President, “We were pleasantly surprised that NV-387 ishighly active upon oral administration, and now we have found that this is because it indeedcrosses into the bloodstream upon oral administration, enabling systemic antiviral effects.” Hefurther explained that, “NV-387 may be the very first or one of very few nanomedicines that areeffective upon oral administration. Nanomedicines in general are restricted to injectable or topicaldelivery. NV-387 is thus unique in this respect.”
    NV-387 has recently completed Phase I human clinical safety tolerability studies with no reportedadverse events in India, as the Company has reported previously.
    About NanoViricides
    NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a development stage companythat is creating special purpose nanomaterials for antiviral therapy. The Company’s novelnanoviricide® class of drug candidates are designed to specifically attack enveloped virusparticles and to dismantle them. Additionally, nanoviricides mimick the host-side features that theviruses continue to require in spite of mutations, and therefore the viruses would be highlyunlikely to escape the nanvoricide drugs.
    Our lead drug candidate is NV-387 (drug product NV-CoV-2) for the treatment of RSV,COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections.NV-387 has successfully completed a Phase 1a/1b human clinical trial in healthy subjects with noreported adverse events even at the highest and repeated dosages. This trial was conducted by thedrug sponsor, Karveer Meditech Pvt. Ltd., our licensee and collaborator in India.The Company is currently focused on advancing NV-387 into Phase II human clinical trials fortreatment of RSV infection.
    Our other advanced candidate is NV-HHV-1 for the treatment of Shingles rash, HSV-1 “coldsores” and HSV-2 “genital ulcers”. The Company cannot project an exact date for filing an INDfor any of its drugs because of dependence on a number of external collaborators and consultants.The Company is also developing drugs against a number of viral diseases including oral andgenital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu,H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus,among others. NanoViricides’ platform technology and programs are based on the TheraCour®nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricidesholds a worldwide exclusive perpetual license to this technology for several drugs with specifictargeting mechanisms in perpetuity for the treatment of the following human viral diseases:Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus(HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV),Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus,Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license forpoxviruses and/or enteroviruses if the initial research is successful. The Company’s technology isbased on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas fromTheraCour Pharma, Inc. The Company’s business model is based on licensing technology fromTheraCour Pharma Inc. for specific application verticals of specific viruses, as established at itsfoundation in 2005.
    As is customary, the Company must state the risk factor that the path to typical drug developmentof any pharmaceutical product is extremely lengthy and requires substantial capital. As with anydrug development efforts by any company, there can be no assurance at this time that any of theCompany’s pharmaceutical candidates would show sufficient effectiveness and safety for humanclinical development. Further, there can be no assurance at this time that successful results againstcoronavirus in our lab will lead to successful clinical trials or a successful pharmaceuticalproduct.
    This press release contains forward-looking statements that reflect the Company’s currentexpectation regarding future events. Actual events could differ materially and substantially fromthose projected herein and depend on a number of factors. Certain statements in this release, andother written or oral statements made by NanoViricides, Inc. are “forward-looking statements”within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the SecuritiesExchange Act of 1934. You should not place undue reliance on forward-looking statements sincethey involve known and unknown risks, uncertainties and other factors which are, in some cases,beyond the Company’s control and which could, and likely will, materially affect actual results,levels of activity, performance or achievements. The Company assumes no obligation to publiclyupdate or revise these forward-looking statements for any reason, or to update the reasons actualresults could differ materially from those anticipated in these forward-looking statements, even ifnew information becomes available in the future. Important factors that could cause actual resultsto differ materially from the company’s expectations include, but are not limited to, those factorsthat are disclosed under the heading “Risk Factors” and elsewhere in documents filed by thecompany from time to time with the United States Securities and Exchange Commission andother regulatory authorities. Although it is not possible to predict or identify all such factors, theymay include the following: demonstration and proof of principle in preclinical trials that ananoviricide is safe and effective; successful development of our product candidates; our abilityto seek and obtain regulatory approvals, including with respect to the indications we are seeking;the successful commercialization of our product candidates; and market acceptance of ourproducts.
    The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer toresearch findings including clinical trials as the customary research usage and do not indicateevaluation of safety or effectiveness by the US FDA.
    “NOAEL” means “No-Observed-Adevrese-Event-Level”, which is the maximum dosageemployed at which there were no adverse events found in animal studies.
    “MTD” means “Maximum Tolerated Dose”, which is the maximum dosage employed that doesnot compromise survival of the animals.
    FDA refers to US Food and Drug Administration. IND application refers to “Investigational NewDrug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to”Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Productsfor Human Use, which is the European Medicines Agency’s (EMA) committee responsible forhuman medicines. API stands for “Active Pharmaceutical Ingredient”. API means activepharmaceutical ingredient.

    A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

    SHELTON, CONNECTICUT – Monday, June 24, 2024 — NanoViricides, Inc. (NYSE Amer.: NNVC) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad antiviral NV-387 could be an important weapon against bird flu H5N1 viruses.

    NanoViricides has recently found that its host-mimetic clinical drug candidate NV-387 was substantially superior to the three approved drugs against influenza, namely Oseltamivir (Tamiflu®, Roche), Peramivir (Rapivab®, Biocryst), and Baloxavir (Xofluza®, Shionogi, Roche) in a lethal animal model study of Influenza A/H3N2 virus lung infection.

    Further, in this study, NV-387 was also found to protect the lungs of the infected animals from viral damage as well as immune system damage, supporting a strong antiviral effect.

    These results have arrived just as the bird flu H5N1 threat potential has increased significantly due to its spread into several mammalian species. While dairy cattle have suffered relatively mild infections, some other mammals, particularly cats on farms have died of brain infection with this virus. Only four human cases have occurred so far with one person dying in Mexico, while the three other cases all in the USA have recovered.

    NV-387 is anticipated to be a strong drug candidate that would remain effective against HPAI H5N1 even as significant mutations occur. This is because of two main reasons:

    1. The Multi-Basic Site (MBS) in the H5. All HPAI possess a MBS in the H5 which is highly positively charged. The MBS enables strong interaction with sulfated proteoglycans (“S-PG”). Since NV-387 is a host-mimetic of S-PG, it is expected that NV-387 would have a strong effect against the MBS-carrying HPAI H5N1.
    2. The broad-spectrum activity of NV-387. NV-387 is active against many very different viruses including Influenza A, RSV, COVID, Seasonal Coronaviruses, and even Poxviruses. This is because of its host-mimetic feature that copies the invariant attachment site common to all of these viruses, the S-PG. The HPAI H5N1 also uses S-PG for attachment, possibly more profoundly than H3N2, because of the MBS in HPAI. Thus NV-387 is likely to continue to work against the HPAI H5N1 despite mutations that cause resistance to other drugs.

    In contrast, very few single-point mutations could make the HPAI H5N1 virus resistant to the existing drugs.

    Only as few as five mutations in the HA (hemagglutinin) protein of this virus could enable it to gain the ability to efficiently infect humans, and this could lead to a pandemic with much greater fatality rates than with COVID, according to Dr. Redfield, ex-Director of CDC as reported in a NewsNation interview (https://www.newsnationnow.com/health/ex-cdc-director-bird-flu-pandemic/). Bird Influenza viruses use a-2,3-sialic acid receptors whereas human influenza viruses use a-2,6-sialic acid receptors to gain entry into cells. Viruses typically concentrate at heparan sulfate or sulfated proteoglycans (S-PG) prior to gaining cell entry.  

    Influenza viruses have a high rate of mutations, and further they can mix-and-match the eight segments of genome from other influenza viruses, called re-assortment, or pick portions of these segments, called recombination.

    A safe and effective antiviral drug that the virus would not escape by simple mutations or field evolution is the holy grail of antiviral drug development. We believe that the NanoViricides Platform technology meets this challenge.

    NEWS

    MANAGEMENT

    ‍

    Anil R. Diwan, PhDExecutive Chairman, President

    Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company’s 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company’s financing efforts since 2010.

    Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.

    He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.

    Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)

    interim Chief Financial Officer

    Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature – India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.

    Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.

    NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.

    ‍

    Randall W. Barton, PhD.Chief Scientific Officer – Consulting

    Dr. Barton has experience in drug discovery and development of both small molecule and biological drug candidates in virology, immunology, inflammation, and cardiovascular diseases in the pharmaceutical and biotech industry as well as academic research and teaching experience. Most recently, he was Vice-President of Drug Discovery at A&G Pharmaceuticals, a biologics and diagnostics company. He retired at the Director level after 20 years at Boehringer Ingelheim Pharmaceuticals. During his time at Boehringer Ingelheim he performed drug development pre-clinical studies on nevirapine (Viramune), a non-nucleoside inhibitor of HIV reverse transcriptase and an important HIV drug.

    Prior to joining Boehringer Ingelheim, he was on the faculty at the University of Connecticut Medical School where he was the recipient of an NIH Career Development Award conducting research and teaching in immunology. Dr. Barton has authored over 80 scientific publications, and has been the principal investigator leading to 5 patents. He has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and a B.A. from Indiana University.  

    Jayant Tatake, PhD.

    Vice President, R&D

    Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.

    Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.

    SINCERELY,

    DISCLAIMER

    THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

    OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY NNVC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

    Categories
    Report

    SPRC PROFILE

    SciSparc Ltd Logo

    SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

    SPRC announced a non-binding letter of intent to spin off its advanced clinical-stage pharmaceutical portfolio SPRC has four main candidates in various stages of clinical development

    SciSparc is advancing its clinical research with a robust pipeline of trials targeting major neurological disorder

    READ THE INVESTOR PRESENTATION HERE

    Hello Everyone,

    Yesterday’s profile retested highs again after making a double digit move during yesterdays session.

    We have another company that we want you to put on your radar this week as we head towards the weekend.

    Pull up SPRC Immediately.

    In the dynamic world of biotechnology and pharmaceuticals, SciSparc Ltd. (Nasdaq: SPRC) is carving out a unique niche. Amidst significant market fluctuations earlier this year, the company is demonstrating resilience and innovation through strategic clinical and corporate initiatives. These efforts are not only stabilizing the company but also setting the stage for substantial long-term growth. With groundbreaking clinical trials and bold spin-off strategies, SciSparc is on a path to unlock considerable value for its shareholders. As the company continues to make strides in medical research and strategic business moves, investors have ample reasons to be optimistic about SciSparc’s future potential.

    SciSparc Ltd. (Nasdaq: SPRC) is emerging as a noteworthy player in the biotech and pharmaceutical sector, despite facing significant market fluctuations earlier this year. The company is actively pursuing clinical and corporate strategies aimed at achieving stability and long-term growth, thereby enhancing shareholder value.

    Clinical Trial Advancements: Autism, Tourette’s, Alzheimer’s

    SciSparc is advancing its clinical research with a robust pipeline of trials targeting major neurological disorders. Key projects include:

    • Tourette’s Syndrome: A phase IIb trial for SCI-110 is underway, presenting a potential breakthrough for this condition.
    • Alzheimer’s Disease: A phase II trial has been completed, offering promising insights for future treatments.
    • Autism Spectrum Disorder: A notable trial for SCI-210, focusing on children with autism, is in progress. This double-blind, placebo-controlled trial aims to address core symptoms of autism, potentially improving the quality of life for affected children and their families.

    SciSparc’s recent patent acquisitions, including those for the treatment and prevention of depression, further bolster its competitive edge and intellectual property portfolio.

    Spin-Off transaction

    The company has four main candidates in various stages of clinical development.

    SPRC also has a controlling interest in a company that sells hemp-oil-based products on Amazon.

    Back in April, SPRC pulled an unorthodox move and acquired a company called AutoMax Motors Ltd., which is a leading Israeli auto importer………….. Strange move for a Pharma company, no?

    If you keep following the story then just last week when SPRC announced a non-binding letter of intent to spin off its advanced clinical-stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals Inc. (which holds the hemp/Amazon business).

    Those assets are valued at roughly 11.6Mill under the agreement.

    The company is still in negotiations with Canada-based Miza III Ventures Inc. about the spinoff, but the press release says SPRC will gain a controlling interest in Miza as part of the deal.

    One could ultimately conclude that SPRC itself will be focused on the auto importing business, while the canna business will move to Canada under Miza.

    Automax reported strong revenues of more than $112M in 2023.

    You can see that activity started picking up Tuesday when the company put out news regarding a new patent application. SPRC exploded all the way to 1.31 after closing at .82 the day before. It has pulled back quite a bit off of the recent highs and is continuing to see above average interest. This is a great time to start researching this one.

    SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

    TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that an additional patent application with the United States Patent and Trademark Office (“USPTO”) was submitted as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems and invented with Professor Joseph Tam from the Hebrew University’s technology transfer company, Yissum. The patent application is for the novel proprietary composition of Palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™ with Clearmind’s innovative MEAI compound (5-methoxy-2-aminoindane) for treating metabolic syndrome and obesity.

    According to data collected by the Centers for Disease Control and Prevention from the period 2017-2020, the prevalence of obesity in the United States of adults aged 20 and over was 41.9%.

    According to Emergen Research, the global obesity treatment market size was $15 billion in 2022 and is expected to grow at a compound annual growth rate of 10.0% during the forecast period. Rising prevalence of obesity and technological advancements in weight loss equipment are key factors driving market revenue growth.

    Overall, as part of this collaboration, twelve other patent applications have been filed by Clearmind with the USPTO for various compositions, including the proprietary composition of SciSparc’s PEA with Clearmind’s MEAI compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.

    PRODUCTS

    SCI-110

    SCI-110, our proprietary drug candidate, containing Dronabinol (FDA approved synthetic form of THC), with the endocannabinoid palmitoylethanolamide (PEA).

    Designed to stimulate cannabinoid receptors across the Central Nervous System and inhibit the metabolic degradation of endocannabinoids in order to improve uptake of THC, the expected benefits of SCI-110 are an increase in efficiency of oral administration, and in turn a decrease in dosage requirements, side effects and adverse events.

    This product is being developed under the accelerated regulatory path of 505 (b)(2) application focused on augmenting FDA-approved natural and synthetic cannabinoids to create alternate therapies that potentiate the effects of cannabinoids and target the receptors implicated in modulating the central nervous system.

    This approach qualifies us for access to the  FDA’s 505 (b)(2) regulatory strategy, created to facilitate the submission of novel drug candidates that meet specific criteria to the FDA for review. The 505 (b)(2) application provides us with several advantages as compared to a typical New Drug Application, including potential; lower risk and development costs, and a potentially expedited time to market.

    Indications currently being investigated for treatment with SCI-110 include:

    – Tourette Syndrome- (TS)
    – Obstructive Sleep Apnea (OSA)
    – Alzheimer’s Disease and Agitation

    SCI-210

    Our proprietary drug candidate containing cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA.

    This product is initially being developed under the regulation of the Israeli Medical Cannabis Agency (IMCA) – the agency that leads the regularization of the medical cannabis field in Israel and is the first of its kind in the world. It is a complex, unique, innovative and original process. Conducting clinical trials and development under the regulation of the HQR ostensibly enables rapid and specific registration processes in a track that is unique to Israel.

    The company intends to further develop the product for markets outside Israel as well. Indications currently being investigated for treatment with SCI-210 include
    – Autism Spectrum Disorder (in  clinical trials)
    – Status Epilepticus – a form of seizures that are severe and sometimes fatal. This indication is currently investigated in pre-clinical settings.

    SCI-160

    SCI-160 is an innovative, proprietary synthetic CB2 receptor agonist created, among others, for the treatment of pain and is currently in pre-clinical studies. The CB2 receptor agonist used in this formulation – HU-433 – was invented and synthesized by Professor Raphael Mechoulam, Ph.D., Chairman of the SciSparc Scientific Advisory Board, and is protected under a patent granted in the U.S. and Europe.

    CannAmide ™

    CannAmide™ is an immediate unique palmitoylethanolamide (PEA) oral formulation for the reduction of chronic pain and inflammation. PEA is a cannabinoid mimetic lipid molecule found throughout the body, including the central nervous system. Similar to cannabinoids, PEA has been shown to have neuroprotective, anti-inflammatory, analgesic and anti-convulsant properties.

    CannAmide is currently available in tablet form, with each dose containing 400mg active pharmaceutical ingredient. It has been designated a product license issuance from the Natural and Non-prescription Health Products Directorate (NNHPD) from Health Canada, for sale as a supplement within the nutraceuticals market.

    SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

    SciSparc will receive additional payments and execution fees if certain milestones are met

    TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that it has signed a non-binding letter of intent (“LOI”) with an undisclosed biotechnology company to pursue the out-licensing of its SCI-160 program (the “Assets”) for the treatment of pain.

    According to the LOI, the biotechnology company would receive exclusive, royalty-bearing global licenses to develop and sublicense the Assets. In exchange, SciSparc would be entitled to receive payment of $3 million in ordinary shares and pre-funded warrants of the biotechnology company, as well as potentially additional payments and execution fees of approximately $3 million in cash, if certain milestones will be met.

    SCI-160 is an innovative, proprietary synthetic cannabinoid formulation for the treatment of pain. Based on pre-clinical studies conducted by the Company, the proprietary combination of cannabinoids and Palmitoylethanolamide has been found to be involved in mediating analgesic effects in the peripheral nervous system without causing significant side effects in both acute and chronic pain.

    Moreover, in certain studies, SCI-160 was found to be well tolerated, did not cause any significant adverse clinical effects, and had a comparable analgesic effect to high-dose morphine and, in some individual instances, exerted even greater potency. While prescription opioids are effective treatments for moderate-to-severe pain, abuse of such opioids is a significant public health issue according to the Centers for Disease Control and Prevention. According to The National Center for Health Statistics, drug overdose deaths involving prescription opioids rose from 3,442 in 1999 to 14,716 in 2022.

    “This LOI will allow us to focus on the Company’s core pharmaceutical activities that involve three late-stage programs for the treatment of Alzheimer’s disease, Tourette syndrome, and autism. We believe that the Company’s strong portfolio will enable us to maximize shareholder value,” said Oz Adler, SciSparc’s Chief Executive Officer.

    SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

    According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million

    TEL AVIV, Israel, July 08, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today it signed a non-binding letter of intent (the “LOI”) to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals Inc. (collectively, the “Target Assets”). The LOI references a proposed asset and share purchase agreement (the “Agreement”), the definitive agreement of which is to be negotiated between the Company and Miza III Ventures Inc. (“Miza”) (TSXV: MIZA.P), a publicly traded company on the Toronto Stock Exchange Venture in Canada.

    The Agreement is based on the approximate total USD 3.3 million (CAD 4.5 million) enterprise value of Miza, when including its USD 1.0 million cash position, and an approximate USD 11.6 million (CAD 15.8 million) value of SciSparc’s assets.

    Pursuant to the LOI, SciSparc will sell, assign, convey and transfer to Miza the Target Assets in consideration for 63,300,000 common shares of Miza and up to 48,000,000 Miza contingent rights based on pre-determined milestones. Following the closing of such transaction, SciSparc would hold a controlling interest in Miza, the exact percentage of which is contingent on agreeing definitive terms between the parties. The resulting entity, of which SciSparc will hold a stake in the resulting entity ranging from a minimum of approximately 75% to a maximum of 84.53%, will be active in both the pharmaceutical and supplement sectors.

    The Agreement aligns with SciSparc’s strategy of creating value for its shareholders and follows the merger agreement and transaction concerning AutoMax Motors Ltd., as previously announced by SciSparc on April 11, 2024.

    SciSparc’s pharmaceutical portfolio includes SCI-110 for treating persons with Tourette syndrome, which is subject to a phase IIb clinical trial, SCI-110 for treating persons with Alzheimer’s disease, the phase II clinical trial of which has been completed, and SCI-210 for treating children with autism, subject to a randomized, double-blind and placebo-controlled trial that commenced in the first quarter of 2024.

    SciSparc to Acquire AutoMax

    TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it signed a merger agreement (the “Agreement”) with AutoMax Motors Ltd. (“AutoMax”), a leading vehicle importer company in Israel.

    According to the Agreement, the Company will acquire 100% of AutoMax and establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into AutoMax (the “Acquisition”). Following the Acquisition, it is contemplated that SciSparc shareholders will hold together approximately 50.01% of the share capital of the post-closing combined company (the “Combined Company”).

    The Acquisition follows the Company’s announcement in June 2022, in which the Company’s board of directors resolved to review potential strategic transactions to maximize shareholder value. The Company’s ongoing business operations, including its late-stage pharmaceutical segment, will continue to operate.

    As a result of the Acquisition, all outstanding shares of AutoMax will be converted into the right to receive ordinary shares of SciSparc. Following the closing, it is contemplated that AutoMax’s equity holders will hold together approximately 49.99%, subject to adjustments, of the Combined Company’s share capital. At the closing of the Acquisition, SciSparc has committed to hold at least $4.25 million in net cash.

    The Acquisition is subject to various approvals, including compliance with any regulatory requirements, including certain Israeli court approvals and SciSparc and AutoMax shareholder approvals. Mr. Amitai Weiss, the chairman of SciSparc, is also the chairman of AutoMax.

    NEWS

    SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 millionTodaySciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification22 hours agoSciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss1 day agoSciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded CompanyJul 8, 2024SciSparc Secures Strategic Advantage with Grant of European PatentMay 31, 2024SciSparc to Acquire AutoMaxApr 11, 2024SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating DepressionMar 27, 2024SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer ResearchMar 21, 2024SciSparc Granted Another Patent, Strengthening its Core Technology in CanadaMar 18, 2024SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical TrialMar 14, 2024SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule StructureMar 12, 2024SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum DisorderMar 8, 2024SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in EuropeMar 7, 2024SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management TechnologyMar 6, 2024SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of DosingFeb 29, 2024SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine CompoundsFeb 27, 2024SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based CompoundsFeb 20, 2024Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds .

    ‍

    MANAGEMENT

    Amitay Weiss

    Chairman

    Mr. Weiss joined the Company in August 2020. He is founder and Chief Executive Officer of Amitay Weiss Management Ltd. Prior to forming his company, he held several positions at Bank Poalei Agudat Israel Ltd., most recently as Vice President of Business Marketing & Development. He currently chairs and serves as director on the boards of several public companies. Mr. Weiss earned his B.A in Economics from New England College, his M.B.A and LL.B from from Ono Academic College in Israel – a branch of the University of Manchester.

    Adi Zuloff-Shani, PhD.

    Chief Technologies Officer

    Dr. Zuloff-Shani joined the Company in February 2016, bringing more than 20 years of experience as a research and development executive in the bio-tech industry and launching start-ups in the healthcare industry. Dr. Zuloff-Shani brought 2 products from bench to market and is currently leading the development of several pharmaceutical products designated to the US, EU and Israeli markets.

    Prior to joining us, she served as Vice President Development at Macrocure Ltd. (Nasdaq: “MCUR”) where she lead all research and development activities. Dr. Zuloff-Shani earned her Ph.D. in Human Biology and Immunology from Bar- Ilan University, Israel.

    Oz Adler, CPA

    Chief Financial Officer and Chief Executive Officer

    Mr. Adler joined the Company in September 2017, and since April 2018 serves as the Company Chief Financial Officer .Mr. Adler has a wide variety of managerial, financial, tax and accounting experience. Prior to joining the Company, Mr. Adler was employed as a CPA at Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global. He currently chairs and serves as director on the boards of several private and public companies. Mr. Adler holds a B.A. in Accounting and Business Management from The College of Management, Israel.

    SINCERELY,

    DISCLAIMER

    THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

    OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF NINE THOUSAND USD BY SHORE THING MEDIA LLC FOR A ONE DAY SPRC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

    Categories
    Report

    WLDS

    Wearable Devices Ltd. logo

    CHECK OUT THE INVESTOR PRESENTATION HERE

    Cash and Deposits at December 31, 2023 were $4.9 million

    WLDS recently signed collaboration agreement with Qualcomm to elevate XR experiences with Mudra neural technology

    The company has successfully delivered first manufacturing batch of the Mudra Band for Apple Watch

    Received purchase order from a leading Japanese industrial automation company for the MDK

    Fortune 500 Consumer Electronics Corporation Has Purchased an Evaluation License for Wearable Devices’ MDK

    __________________________

    Hello Everyone,

    We have another profile back on our radar for tomorrow’s session that we want you to research immediately.

    You might remember this one from back in November of last year when we profiled it.

    We brought WLDS to your attention back on Nov. 1 when it was sitting under .50.

    Just 6 sessions later on the 8th we saw it explode all the way up to 1.12 for a massive 100%+ run.

    We want you to turn your attention to WLDS again and begin your research on it immediately.

    WLDS is a growth company developing a non-invasive neural input interface in the form of a wrist wearable band for controlling digital devices using subtle finger movements. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc. ​

    Since their technology was introduced to the market in 2014, they have been working with both Business-to-Business (B2B) and Business to Consumer (B2C) customers as part of their push-pull strategy.

    They are now in the transition phase from research and development to commercialization of our technology into B2B products. At the same time, they are in the final stage of manufacturing their first B2C consumer product, the “Mudra Band”, an aftermarket accessory band for the Apple Watch which allows touchless operation and control of the watch. Headquartered in Israel, the company was founded in March 2014 by Asher Dahan, Guy Wagner and Leeor Langer, with renowned expertise in the fields of analog sensors, signal processing, deep learning and machine learning algorithms, software, and human-computer interaction.

    Wearable Devices Announces Full Year 2023 Financial Results and Provides Corporate Update

    2023 Achievements Position Wearable Devices for Growth in 2024

    YOKNE’AM ILLIT, Israel, March 15, 2024 (GLOBE NEWSWIRE) — Wearable Devices Ltd.(Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced its financial results for the year ended December 31, 2023.

    Asher Dahan, Chief Executive Officer and Chairman of the Board of Wearable Devices, commented, “2023 was characterized by strategic capital allocation and the execution of our growth strategy as we successfully completed delivery of our first manufacturing batch of the Mudra Band for Apple Watch, and entered into several partnerships with companies and contractors at the forefront of their respective industries. Our net loss increased in pursuit of these milestones, mainly due to strategic investments primarily in sales and marketing and research and development as we continue to innovate and showcase our technology, as well as an enhanced focus on business development on the B2B side of our business.

    “Partnerships represent a key part of our business, and we expect our B2B offerings to be a significant driver of revenue for us as we grow. At the beginning of 2024, we launched the B2B Mudra Developer Kit, or MDK, providing our B2B customers with enhanced capabilities and additional features that improve on our traditional Mudra Inspire B2B offering. The MDK allows OEMs to design new, customized gestures along with existing hand and wrist signals to create a user interface specifically tailored to their needs. Subsequent to the end of the year, we announced a collaboration agreement with Qualcomm, a Fortune 500 company, for the development of products using the Qualcomm Snapdragon Spaces XR Developer Platform, and we announced an agreement at the end of 2023 with a leading global defense company to design neural gesture technology for situations where silent activation is crucial. We anticipate interest in our B2B product to grow as the market for wearable devices and AI-based technology expands, with more and more customers recognizing the value that our products can add to their operations.

    “Our B2C product, the Mudra Band, is an award-winning aftermarket band for the Apple Watch that allows for touchless control of multiple Apple products. We’re seeing considerable interest in the Mudra Band, and during 2023 we commenced shipment of our first manufacturing batch to preorder customers. We continue to receive orders for the product and have seen demonstrated interest at leading trade shows like CES and MWC, where this technology has been documented and recognized as a leading innovation in the tech field. We’re intently focused on increasing our production capacity to meet anticipated demand for the Mudra Band, and we look forward to the continued innovation of this product as our technology and capabilities improve.”

    Mr. Dahan concluded, “We have a comprehensive strategy with innovative B2B and B2C offerings to maximize our presence in what we believe to be a market that is poised for tremendous growth. We are very encouraged by the progress that we made in 2023 and believe that Wearable Devices is positioned for a transformative year in 2024 as we continue to invest in our operations, bring innovative products to market, and showcase the breadth and depth of our technology.”

    2023 and Recent Business Highlights

    • Signed collaboration agreement with Qualcomm to elevate XR experiences with Mudra neural technology
    • Showcased neural input technology at leading industry conferences, including CES 2024, MWC 2024, SPIE AR VR MR 2024, Tiny ML Summit 2023, and XR Fair Tokyo 2023
    • Opened new U.S.-based office in Silicon Valley to expand the Company’s presence and foster relationships in the tech and wearables markets
    • Released MDK for B2B customers allowing OEMs to create a user interface specifically tailored to their operational needs
    • Successfully delivered first manufacturing batch of the Mudra Band for Apple Watch
    • Filed patent application with the U.S. Patent and Trademark Office for touchless pinch-to-zoom technology for augmented and virtual reality
    • Expanded marketing and sales effort with the launch of new Mudra Band website
    • Completed first stage of deployment testing for a leading XR glasses OEM, satisfying criteria outlined in memorandum of understanding
    • Introduced revolutionary spatial depth control allowing for depth navigation that adds another dimension to user interaction
    • Received purchase order from a leading Japanese industrial automation company for the MDK
    • Joined Open XR and Kronos Group as a voting member to help influence and drive industry growth

    Full Year 2023 Financial Highlights:

    • Research and Development Expenses: Research and development expenses increased 46% to $3.3 million in the full year of 2023 compared to the full year of 2022 as the Company continued to focus on creating disruptive, industry leading technology that leverages AI and proprietary algorithms, software and hardware.
    • Sales and Marketing Expenses: Sales and marketing expenses increased 47% to $2.0 million in the full year of 2023 compared to the full year of 2022 related to the Company driving awareness of its technology and products across various channels including participation at multiple leading industry conferences.
    • Net Loss: Net loss increased to $(7.8 million), or $(0.48) per diluted share, for the year ended December 31, 2023, as compared to a net loss of $(6.5 million), or $(0.53) per diluted share, for the year ended December 31, 2022.
    • Cash Position: Cash and Deposits at December 31, 2023 were $4.9 million.
    • Inventory: Inventory significantly increased to $1.0 million the end of 2023, as part of the completion of the transition phase from R&D to production and to serve our planned B2C business growth in 2024.

    For further details on the Company’s financial results for the year ended December 31, 2023, please refer to the company’s annual report on Form 20-F which is being filed with the SEC today.

    Wearable Devices Signs Reseller Agreement to Scale its Licensing Program Reach to Enterprises in South Korea and China

    YOKNE’AM ILLIT, Israel, April 01, 2024 (GLOBE NEWSWIRE) — Wearable Devices Ltd.(Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, is pleased to announce the signing of a reseller agreement with WisePlus, a premier provider of device software solutions. This collaboration aims to scale the Company’s licensing program reach by enabling local, on-site support and customization for enterprises in the markets of South Korea and China, tapping into WisePlus’ extensive network and expertise in these regions.

    Under the terms of the agreement, WisePlus will serve as the official regional reseller of Wearable Devices’ Mudra Technology, allowing WisePlus to demo, negotiate, customize and resell the Company’s Mudra Developer Kit (“MDK”), which is a comprehensive toolset designed to revolutionize the development and integration on Wearable Devices’ neural input technology into solutions, products and services across multiple industries and verticals.

    This partnership will leverage WisePlus’ presence and deep market knowledge in South Korea and China, providing fast local access and support to enterprise customers in these areas.

    The MDK is designed to empower original equipment manufacturers (“OEMs”) and developers with the ability to create custom gestures and use existing signals to monitor and analyze user behavior. This opens up new product and license opportunities across various market segments, from extended reality (“XR”) and smartwatches to Industry 4.0 and beyond.

    “We are very excited to collaborate with Wearable Devices and bring our support, technology and business expertise to promote and create additional demand to the APAC ecosystem,” said Bob Kim, Chief Executive Officer of WisePlus. “The Mudra technology has the needed innovation and product fit to revolutionize the XR-market massive adoption in the near future,” added Mr. Kim.

    Asher Dahan, Chief Executive Officer of Wearable Devices, said: “We are delighted to announce our partnership with WisePlus as our chosen added value reseller in the region. With a proven track record of success in the APAC markets, WisePlus brings invaluable insights and strategic guidance to our collaboration. Their proficiency in providing tailored technology driven solutions, seamless integration, and exceptional customer service perfectly aligns with our vision and objectives. With a focus on customization and integration, we are confident that this partnership will empower us to deliver unparalleled user-experiences”.

    The MDK is available for value-added resellers , distributors, OEMs, and other partners now also through WisePlus. It provides a comprehensive software development kit including multiple Mudra wristband devices and advanced software tools for programming a vast array of gestures into digital actions on both Android and iOS platforms. The MDK package supports Bluetooth communication, is HID-compatible, and employs deep learning algorithms to translate discreet, intuitive gestures into commands for a wide range of applications and devices.

    For more information on the Mudra Developer Kit, please visit Wearable Devices: https://www.wearabledevices.co.il/mdk

    About WisePlus

    WisePlus is a pioneering technology firm specializing in advanced embedded system software and on-device AI solutions. Its core expertise lies in developing high-performance, intelligent software that operates seamlessly on a wide array of devices. By integrating cutting-edge artificial intelligence directly onto devices, WisePlus enables smarter, more efficient, and autonomous operations across various applications, from IoT devices to industrial machinery. WisePlus’ commitment is to revolutionize how devices operate, offering enhanced decision-making capabilities and improved user experiences without the need for constant cloud connectivity. Led by Chief Executive Officer Bob Kim, WisePlus is dedicated to pushing the boundaries of what’s possible within the digital domain, fostering innovation that drives the future of technology.

    Wearable Devices Teams up with Qualcomm to Elevate Extended Reality Experience

    This Collaboration Aims to Transform XR Industry Using the Mudra’s Touchless Control Technology

    YOKNEAM ILLIT, ISRAEL, Feb. 28, 2024 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced a collaboration agreement with Qualcomm Technologies, Inc. This collaboration will help those looking to use Wearable Devices’ innovative Mudra technology when developing products using the Qualcomm Snapdragon Spaces™ XR Developer Platform, redefining interaction in augmented reality (“AR”) and virtual reality (“VR”) environments.

    The Mudra technology, known for its touchless control capabilities, has been optimized to work with Snapdragon Spaces, enhancing the user experience with intuitive, gesture-based interactions. This collaborative approach aims to showcase the innovative potential of combining Mudra’s touchless control technology with Snapdragon Spaces, setting a new standard for immersive digital experiences.

    “Partnering with Qualcomm Technologies marks a significant milestone in our journey to revolutionize the XR industry,” said Offir Remez, Executive Vice President of Business Development at Wearable Devices. “The integration of our cutting-edge Mudra technology with Snapdragon Spaces is enhancing the XR experience and reimagining how we interact with digital worlds. Together, we’re paving the way for a future where seamless, intuitive gestures bring us closer to technology, making immersive environments more accessible and engaging than ever before,” added Mr. Remez

    Fortune 500 Consumer Electronics Corporation Has Purchased an Evaluation License for Wearable Devices’ MDK

    The companies will explore together with the Fortune 500 company’s AI division different use cases of Mudra neural AI controller

    YOKNEAM ILLIT, ISRAEL, July 09, 2024 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, announced today that a Fortune 500 consumer electronics corporation (“Customer”) has purchased a special license for its state-of-the-art Mudra Development Kit (“MDK”) to evaluate certain deep-level capabilities.

    The MDK enables developers to create unique experiences with the Mudra Band and Mudra Application Programming Interface. This powerful toolset will enable the Customer’s development team to seamlessly integrate advanced functionalities into their upcoming products, enhancing user experience through innovative gesture control technology.

    The Customer, ranked among the Fortune 500 companies, is renowned for its cutting-edge technology and high-quality consumer electronics products, which include smartphones, televisions, home appliances, and more. With a strong global presence and a reputation for innovation, this company is ideally positioned to leverage the capabilities of the MDK for developing next-generation user interfaces.

    Asher Dahan, Chief Executive Officer of Wearable Devices, commented, “We are excited to see our Mudra technology gaining recognition by a prominent player in the consumer electronics market. This special license to evaluate possible deep-level integration marks a significant step forward for us, as it demonstrates the growing recognition of our technology’s potential to revolutionize user interactions, particularly in applications such as extended reality (XR), televisions, 3D displays, and laptops. We look forward to seeing the innovative applications and products that will emerge from this collaboration.”

    The MDK is designed to provide developers with the tools needed to implement sophisticated gesture control features in their applications. By leveraging Wearable Devices’advanced neural input technology, developers can create intuitive and responsive user interfaces that enhance the overall user experience.

    NEWS

    MANAGEMENT

    Asher Dahan

    CEO & Co-Founder Director

    Project execution expert. Talent in business leading and strategic planning. Manager and team leader. High expertise in major corporate decisions, experience managing the overall operations and resources of the Company.

    Guy Wagner

    Company President & Chief Scientist, Co-Founder Director

    Hardware expert and main inventor. Multi- disciplinary expertise in board design, biomedical signal processing, embedded programming and sensor design.

    Leeor Langer

    CTO & Co-Founder

    Algorithms expert. Machine learning, and signal / image processing developer. Lead algorithms engineer in industry and academia. Wrote several papers and articles.

    SINCERELY,

    DISCLAIMER

    THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

    OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SHORE THING MEDIA LLC FOR A ONE DAY WLDS AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.